Cantor Fitzgerald initiated coverage on ARS Pharmaceuticals
$SPRY
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $30.00 | Sector Outperform | Scotiabank |
| 2/10/2025 | $40.00 | Outperform | Oppenheimer |
| 8/20/2024 | Overweight | Cantor Fitzgerald | |
| 8/13/2024 | $18.00 → $22.00 | Outperform → Strong Buy | Raymond James |
| 8/12/2024 | $19.00 → $20.00 | Outperform | Leerink Partners |
| 7/25/2024 | $18.00 | Outperform | Raymond James |
| 3/5/2024 | $6.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 2/20/2024 | Mkt Perform → Outperform | William Blair |
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00
Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00
Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight
10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
SCHEDULE 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership 93% commercial coverage achieved with streamlined prior authorization process with approval rates at the pharmacy benefit manager (PBM) comparable to overall epinephrine market EURneffy® approved in the United Kingdom and launched in Germany, now representing a global footprint with this first and only needle-free epinephrine treatment Conference call to be held today, August 13, 2025, at 5:
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late Q3 2025 U.K. is the largest market outside the U.S. for adrenaline (epinephrine) auto-injector sales SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the United Kingdom (U.K.) Medicines and Healthcare produ
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership 93% commercial coverage achieved with streamlined prior authorization process with approval rates at the pharmacy benefit manager (PBM) comparable to overall epinephrine market EURneffy® approved in the United Kingdom and launched in Germany, now representing a global footprint with this first and only needle-free epinephrine treatment Conference call to be held today, August 13, 2025, at 5:
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering